CA3223191A1 - Compositions et methodes de diagnostic, de detection et de traitement de maladies liees aux eosinophiles - Google Patents

Compositions et methodes de diagnostic, de detection et de traitement de maladies liees aux eosinophiles Download PDF

Info

Publication number
CA3223191A1
CA3223191A1 CA3223191A CA3223191A CA3223191A1 CA 3223191 A1 CA3223191 A1 CA 3223191A1 CA 3223191 A CA3223191 A CA 3223191A CA 3223191 A CA3223191 A CA 3223191A CA 3223191 A1 CA3223191 A1 CA 3223191A1
Authority
CA
Canada
Prior art keywords
pro
embp1
eosinophil
piece
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223191A
Other languages
English (en)
Inventor
Gerald J. Gleich
Kristin M. Leiferman
Kathryn A. Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA3223191A1 publication Critical patent/CA3223191A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des méthodes de diagnostic, de détection et de traitement d'une maladie liée aux éosinophiles ou d'une inflammation liée aux éosinophiles chez un sujet. L'invention concerne également des compositions comprenant la pro-pièce de protéine basique majeur de granule pro-éosinophile-1 ou un fragment de celle-ci et leurs procédés d'utilisation.
CA3223191A 2021-09-03 2022-09-02 Compositions et methodes de diagnostic, de detection et de traitement de maladies liees aux eosinophiles Pending CA3223191A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240470P 2021-09-03 2021-09-03
US63/240,470 2021-09-03
PCT/US2022/075946 WO2023034993A1 (fr) 2021-09-03 2022-09-02 Compositions et méthodes de diagnostic, de détection et de traitement de maladies liées aux éosinophiles

Publications (1)

Publication Number Publication Date
CA3223191A1 true CA3223191A1 (fr) 2023-03-09

Family

ID=85411632

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223191A Pending CA3223191A1 (fr) 2021-09-03 2022-09-02 Compositions et methodes de diagnostic, de detection et de traitement de maladies liees aux eosinophiles

Country Status (2)

Country Link
CA (1) CA3223191A1 (fr)
WO (1) WO2023034993A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025034646A1 (fr) * 2023-08-04 2025-02-13 NexEos Diagnostics, Inc. Compositions polymères acides et méthodes d'utilisation associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107459A (en) * 1991-02-08 2000-08-22 Diatide, Inc. Technetium-99m labeled peptides for diagnostic imaging
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
EP2825561A4 (fr) * 2012-03-15 2016-03-09 Permeon Biolog Inc Compositions pénétrant les cellules pour l'administration d'anticorps intracellulaires et de groupes fonctionnels intracellulaires semblables aux anticorps, et procédés d'utilisation
US9789212B2 (en) * 2012-05-18 2017-10-17 University Of Utah Research Foundation Methods for diagnosing and monitoring eosinophilic esophagitis
WO2015057668A1 (fr) * 2013-10-15 2015-04-23 Medimmune, Llc Procédés de traitement de broncho-pneumopathie chronique obstructive à l'aide du benralizumab
US10422004B2 (en) * 2014-08-08 2019-09-24 Children's Hospital Medical Center Diagnostic method for distinguishing forms of esophageal eosinophilia

Also Published As

Publication number Publication date
WO2023034993A1 (fr) 2023-03-09

Similar Documents

Publication Publication Date Title
JP7590724B2 (ja) 炎症性腸疾患の治療薬
US8795627B2 (en) Treatment of liver disorders by administration of RAP conjugates
RU2565391C2 (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
JP2021191781A (ja) フラジェリン組成物および使用
JP6552117B2 (ja) 敗血症の予防治療剤
ES2320421T3 (es) Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones.
JP2004528286A5 (fr)
JP2010501596A (ja) 抗体含有組成物を用いた非感染性の病状の処置および／または予防
KR20230107239A (ko) 항 b7-h3 항체-약물 콘주게이트 투여에 의한 중피종의 치료
CN112533640A (zh) 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向
RU2740311C2 (ru) НАЦЕЛЕННЫЕ НА uPARAP КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО
US10336827B2 (en) Compositions and methods to treat solid tumors
US12318434B2 (en) Alkaline phosphate-based oncology treatments
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
CN119604314A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
CA3223191A1 (fr) Compositions et methodes de diagnostic, de detection et de traitement de maladies liees aux eosinophiles
CN109715191A (zh) 将赘生性细胞转化成非赘生性细胞的药物缔合物及其用途
CN109715190A (zh) 将赘生性细胞转化成非赘生性细胞的生长因子受体激动剂和黏附蛋白抑制剂的药物缔合物及其用途
US20240226306A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
US11733232B2 (en) Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same
EP4386011A1 (fr) Protéine de fusion d'interféron alpha d'anticorps ciblant gpc3 et son utilisation
RU2446174C2 (ru) Пептид с антипролиферативной активностью и фармацевтическая композиция для лечения пролиферативных заболеваний
WO2015058040A1 (fr) Suppression d'une transformation cellulaire et d'une dysplasie par application topique de lefty
US10287328B2 (en) Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
CN120590505A (zh) 一种重组补体蛋白及在制备抗白血病药物中的应用

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250805

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260217